BiVictriX Therapeutics PLC Director Dealing (7970M)

TIDMBVX

RNS Number : 7970M

BiVictriX Therapeutics PLC

23 September 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

23 September 2021

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

Director Dealing

Alderley Park, 23 September 2021 BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, announces the following dealing in the Company's ordinary shares of 1 pence each ("Ordinary Shares").

On 22 September 2021, Mr Iain Ross, the Company's Non-Executive Chairman, purchased 100,000 Ordinary Shares at a weighted average price of 19.42 pence each.

Following the transaction, Mr Ross is benefically interested in 300,000 Ordinary Shares, representing 0.45% of the Company's total issued share capital.

-Ends-

 
 For more information, please contact: BiVictriX Therapeutics plc 
   Tiffany Thorn, Chief Executive Officer 
    Iain Ross, Chairman                       Email: [e-mail] 
 
   SP Angel Corporate Finance LLP (NOMAD     Tel: [phone] 
    and Broker) 
   David Hignell, Caroline Rowe (Corporate 
    Finance) 
    Vadim Alexandre, Rob Rees (Sales and 
    Broking) 
 
    Consilium Strategic Communications 
   Ashley Tapp, Suki Virji, Priit Piip       Tel: [phone] 
                                              Email: [e-mail] 
 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst eliminating treatment-related toxicities.

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni(R) therapeutics which are designed to selectively target antigen co-expression fingerprints, or "twin antigens", on tumour cells, which are largely absent from healthy cells. Whereas this concept has been validated in a clinical diagnostic setting to support the diagnosis and monitoring of haematological cancers, it has not yet been widely used in a therapeutic setting.

BiVictriX has identified a diverse panel of novel cancer-specific "twin antigens", across a broad range of cancer indications including Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The Company is using these novel "twin-antigens" to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and currently constitute areas of high unmet medical need.

Find out more about BiVictriX online at www.bivictrix.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
 1.   Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                             Iain Ross 
     -------------------------------  -------------------------------------------------- 
 2.   Reason for the Notification 
     ----------------------------------------------------------------------------------- 
 a)   Position/status                  Non-Executive Chairman 
     -------------------------------  -------------------------------------------------- 
 b)   Initial notification/Amendment   Initial notification 
     -------------------------------  -------------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ----------------------------------------------------------------------------------- 
 a)   Name                             BiVictriX Therapeutics plc 
     -------------------------------  -------------------------------------------------- 
 b)   LEI                              213800ZI85IZNA6N3L53 
     -------------------------------  -------------------------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ----------------------------------------------------------------------------------- 
 a)   Description of                   Ordinary Shares of 1 pence each 
       the Financial                    GB00BNXH3K91 
       instrument, type 
       of instrument 
      Identification 
       code 
     -------------------------------  -------------------------------------------------- 
 b)   Nature of the                    Purchase of 100,000 Ordinary Shares 
       transaction 
     -------------------------------  -------------------------------------------------- 
 c)   Price(s) and                       Price(s)                            Volume(s) 
       volume(s)                                           1. 19.375 pence     43,507 
                                                                               30,848 
                                                            2. 19.45 pence     25,645 
 
                                                            3. 19.45 pence 
                                                                             ---------- 
     -------------------------------  -------------------------------------------------- 
 d)        Aggregated information:      Price(s)                              Volume(s) 
             *    Aggregated volume 
                                                           19.42p (weighted 
                                                           average)             100,000 
             *    Price                                                       ---------- 
     -------------------------------  -------------------------------------------------- 
 e)   Date of the transaction          22 September 2021 
     -------------------------------  -------------------------------------------------- 
 f)   Place of the                     AIM, London Stock Exchange 
       transaction 
     -------------------------------  -------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBBGDCISDDGBX

(END) Dow Jones Newswires

September 23, 2021 07:50 ET (11:50 GMT)